Zhao Yuhua, Yu Limeng, Wang Lili, Wu Yingxi, Chen Haiyang, Wang Qiming, Wu Yufeng
Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Front Oncol. 2023 Jan 20;12:961440. doi: 10.3389/fonc.2022.961440. eCollection 2022.
Malignant pleural effusion (MPE) is a common complication in the late stage of malignant tumors. The appearance of MPE indicates that the primary tumor has spread to the pleura or progressed to an advanced stage. The survival time of the patients will be significantly shortened, with a median survival of only a few months. There are a variety of traditional treatments, and their advantages and disadvantages are relatively clear. There are still many problems that cannot be solved by traditional methods in clinical work. The most common one is intrapleural perfusion therapy with chemotherapy drugs, but it has a large side effect of chemotherapy. At present, with the development of medical technology, there are a variety of treatment methods, and many innovative, significant and valuable treatment methods have emerged, which also bring hope for the treatment of refractory and recurrent MPE patients. Several clinical trials had confirmed that drug-carrying microparticles has less adverse reactions and obvious curative effect. However, there is still a long way to go to completely control and cure MPE, and the organic combination of clinical work and scientific research results is needed to bring dawn to refractory MPE patients.
恶性胸腔积液（MPE）是恶性肿瘤晚期的常见并发症。MPE的出现表明原发性肿瘤已扩散至胸膜或进展到晚期。患者的生存时间将显著缩短，中位生存期仅为几个月。传统治疗方法有多种，其优缺点相对明确。临床工作中仍有许多问题无法通过传统方法解决。最常见的是化疗药物胸腔内灌注治疗，但它有较大的化疗副作用。目前，随着医学技术的发展，治疗方法多种多样，出现了许多创新、显著且有价值的治疗方法，这也为难治性和复发性MPE患者的治疗带来了希望。多项临床试验已证实，载药微粒不良反应较少且疗效明显。然而，要完全控制和治愈MPE仍有很长的路要走，需要临床工作与科研成果有机结合，才能给难治性MPE患者带来曙光。
